TRINETRA › Sectors › Healthcare
Acutaas Chemicals Limited (ACUTAAS) — share price, P/E and fundamentals
Acutaas Chemicals Limited (NSE: ACUTAAS) closed at ₹4,003.60 on 30 Oct 2026, +143.1% over one year, against a 52-week range of ₹1,570.00 – ₹4,024.00.
In the quarter ended 30 Sept 2026 (consolidated, filed 27 Oct 2026) it reported revenue of ₹437 cr and net profit of ₹125 cr, a 28.7% net margin; revenue grew 42.7% and profit grew 74.0% year on year.
On four consecutive filed quarters its trailing P/E is 74.6; since 2 May 2025 its own P/E has ranged from 51.8 to 94.5 (median 68.8), and today's reading is higher than 73% of those 370 trading days.
From the balance sheet dated 30 Sept 2026: return on equity 27.0%, ROCE 34.2%, debt-to-equity 0.00, Piotroski F-score 8 of 9.
Against 65 Healthcare peers on NSE: Net margin higher than 94% of 63 sector peers; PBT margin higher than 98% of 63 sector peers; ROE higher than 90% of 63 sector peers.
Key figures
| Last close | ₹4,003.60 (30 Oct 2026) |
|---|---|
| Change 1 month / 6 months / 1 year | +21.9% / +67.2% / +143.1% |
| 52-week low – high | ₹1,570.00 – ₹4,024.00 |
| Market capitalisation | ₹32,778 cr |
| Trailing P/E | 74.6 |
| Price / book | 17.65 |
| EV / EBITDA | 50.3 |
| Earnings yield | 1.3% |
| TTM EPS | ₹53.64 |
| TTM net profit | ₹439 cr |
| Quarter revenue | ₹437 cr |
| Quarter net profit | ₹125 cr |
| Net margin | 28.7% |
| Revenue growth (YoY) | +42.7% |
| Profit growth (YoY) | +74.0% |
| Return on equity | 27.0% |
| ROCE | 34.2% |
| Debt / equity | 0.00 |
| Current ratio | 3.99 |
| Free cash flow | ₹92 cr |
| Piotroski F-score | 8 / 9 |
| Average daily turnover (50 days) | ₹97.8 cr |
Against Healthcare peers
| Metric | ACUTAAS | Peer median | Percentile |
|---|---|---|---|
| Net margin | 28.65 | 12.67 | 94 |
| PBT margin | 38.31 | 17.57 | 98 |
| ROE | 26.96 | 13.86 | 91 |
| ROCE | 34.23 | 16.59 | 92 |
| Debt / equity | 0.00 | 0.11 | 12 |
| FCF margin | 12.00 | -0.87 | 64 |
| Cash conversion | 1.09 | 1.25 | 42 |
| Trailing P/E | 74.64 | 43.07 | 76 |
Questions
What is the P/E ratio of Acutaas Chemicals Limited?
Acutaas Chemicals Limited's trailing P/E is 74.6, using the close of 30 Oct 2026 and earnings over the four filed quarters to 30 Sept 2026. Since 2 May 2025 its P/E has ranged 51.8–94.5.
What were Acutaas Chemicals Limited's latest quarterly results?
For the quarter ended 30 Sept 2026, Acutaas Chemicals Limited reported revenue of ₹437 cr and net profit of ₹125 cr (consolidated), filed with the exchange on 27 Oct 2026.
What is Acutaas Chemicals Limited's ROE?
Return on equity is 27.0% based on the balance sheet dated 30 Sept 2026.
Does Acutaas Chemicals Limited have debt?
Debt-to-equity is 0.00 on the balance sheet dated 30 Sept 2026.
What is ACUTAAS's 52-week high and low?
Over the last 52 weeks to 30 Oct 2026, ACUTAAS traded between ₹1,570.00 and ₹4,024.00.
Other Healthcare stocks
- Sun Pharmaceutical Industries Limited (SUNPHARMA)
- Divi's Laboratories Limited (DIVISLAB)
- Torrent Pharmaceuticals Limited (TORNTPHARM)
- Laurus Labs Limited (LAURUSLABS)
- Zydus Lifesciences Limited (ZYDUSLIFE)
- Apollo Hospitals Enterprise Limited (APOLLOHOSP)
- Dr. Reddy's Laboratories Limited (DRREDDY)
- Cipla Limited (CIPLA)
- Mankind Pharma Limited (MANKIND)
- Aurobindo Pharma Limited (AUROPHARMA)
- Lupin Limited (LUPIN)
- Max Healthcare Institute Limited (MAXHEALTH)
Source: consolidated SEBI Integrated Filing for the quarter ended 30 Sept 2026 and NSE daily closes. Open the interactive terminal view for charts and the full statements.
TRINETRA is a research and education tool. Nothing on this site is investment advice or a recommendation to buy or sell any security. Markets carry risk; do your own research and consult a SEBI-registered adviser before investing. Figures are as filed with NSE/SEBI and as of the dates shown; they are not live prices.